Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Monday, July 17th, RTT News reports. Stockholders of record on Tuesday, August 29th will be paid a dividend of 0.84 per share on Tuesday, September 12th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th.
Johnson & Johnson has raised its dividend by an average of 6.7% per year over the last three years and has increased its dividend annually for the last 54 consecutive years. Johnson & Johnson has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Analysts expect Johnson & Johnson to earn $7.74 per share next year, which means the company should continue to be able to cover its $3.36 annual dividend with an expected future payout ratio of 43.4%.
Johnson & Johnson (JNJ) traded up 0.01% on Friday, reaching $133.10. The company had a trading volume of 4,270,571 shares. The stock has a market capitalization of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The firm has a 50 day moving average price of $133.09 and a 200-day moving average price of $126.30.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter last year, the business posted $1.74 EPS. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
JNJ has been the subject of several research analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price target for the company in a research note on Monday, April 24th. Cowen and Company reiterated a “buy” rating and issued a $143.00 price objective (up from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. UBS AG reiterated a “buy” rating and issued a $136.00 price objective on shares of Johnson & Johnson in a research note on Monday, May 15th. BMO Capital Markets reiterated a “buy” rating and issued a $132.00 price objective on shares of Johnson & Johnson in a research note on Friday, June 2nd. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 15th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $133.72.
In related news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the last quarter. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares during the last quarter. FMR LLC raised its stake in Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Johnson & Johnson by 4.5% in the second quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock valued at $2,363,788,000 after buying an additional 771,039 shares during the last quarter. Finally, Swiss National Bank raised its stake in Johnson & Johnson by 2.7% in the second quarter. Swiss National Bank now owns 10,738,464 shares of the company’s stock valued at $1,420,591,000 after buying an additional 277,800 shares during the last quarter. 66.06% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Announces $0.84 Quarterly Dividend” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/08/11/johnson-johnson-jnj-declares-quarterly-dividend-of-0-84-updated-updated-updated.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.